Speaker

Andrew Buesking

Sr. Director, Prelude Therapeutics

Andrew Buesking, Sr. Director at Prelude Therapeutics, is speaking at 9th TPD & Induced Proximity Summit (Boston, United States of America, 26–29 Oct 2026) in the session “Identification of First-in-Class KAT6A Degraders Leading to Potent & KAT6A-Selective Oral Development Candidate PRT13722”.

Conferences: 1
Keynotes: 0
Upcoming: 1

Pharmacy & Pharmaceutical Sciences

Upcoming appearances

9th TPD & Induced Proximity Summit
26–29 Oct 2026Boston, United States of America
- SpeakerIdentification of First-in-Class KAT6A Degraders Leading to Potent & KAT6A-Selective Oral Development Candidate PRT13722

More speakers at 9th TPD & Induced Proximity Summit

Stuart Schreiber
Professor, Harvard Medical School
Randy Teel
President & Chief Executive Officer, Arvinas, Inc.
Carla Bauer
Director, Oncology Search & Evaluation, Business Development & Licensing, Merck & Co
Alyn Davies
Associate Director, Medicinal Chemistry, AstraZeneca
Adam Gilbert
Science Partner, Flagship Pioneering
Jason Kantor
Chief Business Officer, Nurix Therapeutics, Inc.

See all 61 speakers on the event page

This profile is built from conference programmes published on kongre.net. It has not been claimed or confirmed by Andrew Buesking, and it lists only the talks, sessions and presentations named in those programmes.

Is this you? Claim this profile — every request is read by a person before anything is linked.

To ask for a correction or for this profile to be removed, email [email protected].